Collegium Pharmaceutical Stock Forecast, Price & News

-0.38 (-1.63 %)
(As of 06/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume133,131 shs
Average Volume445,136 shs
Market Capitalization$810.35 million
P/E Ratio19.82
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive COLL News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Collegium Pharmaceutical logo

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.61 out of 5 stars

Medical Sector

609th out of 2,100 stocks

Pharmaceutical Preparations Industry

296th out of 831 stocks

Analyst Opinion: 1.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 4.4 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions

Is Collegium Pharmaceutical a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Collegium Pharmaceutical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in COLL, but not buy additional shares or sell existing shares.
View analyst ratings for Collegium Pharmaceutical
or view top-rated stocks.

What stocks does MarketBeat like better than Collegium Pharmaceutical?

Wall Street analysts have given Collegium Pharmaceutical a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Collegium Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Collegium Pharmaceutical's next earnings date?

Collegium Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Collegium Pharmaceutical

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) posted its earnings results on Thursday, May, 6th. The specialty pharmaceutical company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.30 by $0.11. The specialty pharmaceutical company earned $87.70 million during the quarter, compared to analyst estimates of $81.21 million. Collegium Pharmaceutical had a net margin of 13.06% and a trailing twelve-month return on equity of 24.52%. The company's revenue for the quarter was up 14.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.01 earnings per share.
View Collegium Pharmaceutical's earnings history

How has Collegium Pharmaceutical's stock been impacted by COVID-19?

Collegium Pharmaceutical's stock was trading at $17.57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, COLL shares have increased by 30.8% and is now trading at $22.99.
View which stocks have been most impacted by COVID-19

What guidance has Collegium Pharmaceutical issued on next quarter's earnings?

Collegium Pharmaceutical issued an update on its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $330 million-$350 million, compared to the consensus revenue estimate of $339.52 million.

What price target have analysts set for COLL?

3 brokerages have issued 12-month target prices for Collegium Pharmaceutical's stock. Their forecasts range from $8.00 to $34.00. On average, they expect Collegium Pharmaceutical's stock price to reach $25.00 in the next year. This suggests a possible upside of 8.7% from the stock's current price.
View analysts' price targets for Collegium Pharmaceutical
or view top-rated stocks among Wall Street analysts.

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the following people:
  • Mr. Michael Thomas Heffernan, Co-Founder & Chairman (Age 57, Pay $110k)
  • Mr. Joseph J. Ciaffoni, Pres, CEO & Director (Age 50, Pay $1.13M)
  • Mr. Paul J. Brannelly, Exec. VP & CFO (Age 48, Pay $725.63k)
  • Dr. Alison B. Fleming, Exec. VP & Chief Technical Officer (Age 46, Pay $580.2k)
  • Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel & Sec. (Age 37, Pay $682.11k)
  • Dr. Richard Malamut, Exec. VP & Chief Medical Officer (Age 61, Pay $652.05k)
  • Ms. Alex Dasalla, Head of Investor Relations
  • Mr. Bart J. Dunn, Exec. VP of Strategy & Corp. Devel.
  • Mr. Scott Dreyer, Exec. VP & Chief Commercial Officer (Age 49)
  • Mr. Jack Maroney, VP of Sales

What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO?

6 employees have rated Collegium Pharmaceutical CEO Joseph Ciaffoni on Joseph Ciaffoni has an approval rating of 68% among Collegium Pharmaceutical's employees.

Who are some of Collegium Pharmaceutical's key competitors?

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), (CGC), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (16.72%), Janus Henderson Group PLC (11.57%), Rubric Capital Management LP (6.87%), Renaissance Technologies LLC (3.59%), Rock Springs Capital Management LP (2.61%) and Great Point Partners LLC (2.44%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann.
View institutional ownership trends for Collegium Pharmaceutical

Which major investors are selling Collegium Pharmaceutical stock?

COLL stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Rock Springs Capital Management LP, Renaissance Technologies LLC, Millennium Management LLC, Emerald Advisers LLC, Bank of Montreal Can, AQR Capital Management LLC, and Dimensional Fund Advisors LP. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer, and Shirley R Kuhlmann.
View insider buying and selling activity for Collegium Pharmaceutical
or view top insider-selling stocks.

Which major investors are buying Collegium Pharmaceutical stock?

COLL stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Rubric Capital Management LP, Great Point Partners LLC, Principal Financial Group Inc., Principal Financial Group Inc., Foundry Partners LLC, Bank of New York Mellon Corp, and Point72 Asset Management L.P..
View insider buying and selling activity for Collegium Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $22.99.

How much money does Collegium Pharmaceutical make?

Collegium Pharmaceutical has a market capitalization of $810.35 million and generates $310.02 million in revenue each year. The specialty pharmaceutical company earns $26.75 million in net income (profit) each year or $0.76 on an earnings per share basis.

How many employees does Collegium Pharmaceutical have?

Collegium Pharmaceutical employs 234 workers across the globe.

What is Collegium Pharmaceutical's official website?

The official website for Collegium Pharmaceutical is

Where are Collegium Pharmaceutical's headquarters?

Collegium Pharmaceutical is headquartered at 100 Technology Center Drive, Stoughton MA, 02072.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.